Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats
Keywords: ACTH; adrenocorticotropic hormone; GH; growth hormone; HPA; hypothalamic-pituitary-adrenal axis; IGF-1; insulin-like growth factor 1; sc; subcutaneous; sst; somatostatin receptor subtypes; Pasireotide; Somatostatin; LCI699; Osilodrostat; 11β-hydroxyl